Lisen Imprinting Diagnostics has been chosen by Merck as one of the healthcare startups for their 2019 Accelerator Program in China. Lisen initially bested out almost 300 other Asian technology companies to qualify among the 17 startups which were given the opportunity to attend their Accelerator workshop in Shanghai held last October 21-23,2019. Lisen topped the final […]
Read More
Wilmington, DE – Feb 13, 2025 – Lisen Imprinting Diagnostic, Inc. (LisenID) has entered a know-how agreement with Mayo Clinic to research and develop innovative early cancer diagnostic solutions. This collaboration combines LisenID’s epigenetic imprinting technology with Mayo Clinic’s clinical expertise to address gaps in early cancer detection. LisenID specializes in Quantitative Chromogenic Imprinted Gene In-Situ […]
Read More
On November 20, 2024, the final list of winners for the Delaware EDGE (Encouraging Development, Growth & Expansion) competition was announced, with Lisen Imprint among the honorees. The EDGE Award is granted to only 10 businesses per cycle, recognizing the most outstanding and innovative enterprises in Delaware. The EDGE Award was established by the Delaware […]
Read More
A press conference and deepening cooperation signing ceremony between Lisen Imprinting and Galixir was held in Shanghai on November 1, 2021. Also present were representatives from Shanghai Zhangjiang Medicine Public Service Platform and Merck China Innovation Center who graced the occasion with congratulatory messages and motivational speeches. Well-known investment institutions such as Baida Finance, BAI […]
Read More